Search - tctmd.com

Displaying 41 - 60 of 202

Sort: Relevancy | Date

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

March 08, 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

News Conference News ACC 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

Michael O'Riordan

March 07, 2023

Wrist-Worn Sensor May Help Detect Elevated Troponin in ACS

News Conference News ACC 2023

Wrist-Worn Sensor May Help Detect Elevated Troponin in ACS

March 06, 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

News Conference News ACC 2023

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

March 05, 2023

For Complex PCI, Intravascular Imaging Lowers Risk of Target Vessel Failure

News Conference News ACC 2023

For Complex PCI, Intravascular Imaging Lowers Risk of TVF

Michael O'Riordan

March 05, 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

News Conference News ACC 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

March 04, 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

March 04, 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

What’s Going to Be Hot at ACC/WCC 2023?

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

February 27, 2023

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short

News Conference News ACC 2022

BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short

April 11, 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

News Conference News ACC 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

April 08, 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

FLAVOUR FFR as Good as IVUS for Intermediate Coronary Stenoses

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

April 04, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.